In July 2020, Missoula-based biotech therapeutics company Inimmune Corporation announced the largest Series A investment in Montana history: a $22 million round led by Two Bear Capital out of Whitefish.
Founded in 2016, Inimmune develops vaccines and immunotherapeutics in allergy, autoimmunity, infectious disease, opioid addiction and cancer with multiple candidates rapidly advancing to Phase I human clinical trials in the next 1-2 years. The company designs, formulates, and evaluates vaccines and immunotherapeutic drugs in their Missoula lab to effectively span the space from pre-clinical discovery to clinical testing.
READ FULL ARTICLE HERE
